The company’s decision follows positive results from Phase 1/2 clinical study of AST-915 which showed that the drug is safe and well tolerated and demonstrated a clear effect on tremor power.
The study was conducted by the National Institute of Neurological Disorders and Stroke (NINDS) at the National Institutes of Health (NIH) under a CRADA agreement between the NIH and Ariston Pharmaceuticals, a wholly owned subsidiary of Manhattan Pharma.
Manhattan Pharma plans to continue to work with the NIH and to proceed toward Phase 2 with the AST-915 development program.